AtriCure, Inc. (ATRC)
After hours:
| Previous Close | 23.17 |
| Open | 23.08 |
| Bid | 22.98 x 700 |
| Ask | 23.06 x 600 |
| Day's Range | 22.92 - 23.58 |
| 52 Week Range | 22.27 - 59.61 |
| Volume | |
| Avg. Volume | 726,154 |
| Market Cap | 1.115B |
| Beta (5Y Monthly) | 1.37 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.66 |
| Earnings Date | May 01, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 53.13 |
ZacksAtriCure's (ATRC) cryoSPHERE+ Probe to Aid in Pain Management
AtriCure (ATRC) unveils its cryoSPHERE+ cryoablation probe, which is intended to reduce freeze times and aid in postoperative pain management.
Business WireAtriCure Announces Launch of the cryoSPHERE®+ Probe for Post-Operative Pain Management
MASON, Ohio, April 18, 2024--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it has launched the cryoSPHERE®+ cryoablation probe, leveraging new insulation technology to reduce freeze times by 25% versus AtriCure’s legacy cryoSHPERE® device. The product is currently in an extended limited launch period in the United States, with
Business WireAtriCure to Announce First Quarter 2024 Financial Results
MASON, Ohio, April 10, 2024--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its first quarter 2024 financial results on Wednesday, May 1, 2024.
